The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.

Article Details

Citation

Copy to clipboard

Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG

The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.

Inflamm Bowel Dis. 2016 Jul;22(7):1737-43. doi: 10.1097/MIB.0000000000000808.

PubMed ID

27306074 [ View in PubMed

]

Abstract

Multiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Ustekinumab	Interleukin-23 (Protein Group)	Protein group	Humans	Yes	Inhibitor	Details